Great News!!! Corona ki mandu dorikindi... DOW up 800 points

[JambaKrantu]

3 minutes ago, mirchi_bajji said:

chloroquine sangathi emti..... thatha millions of doses konnadu?

They will just stockpile it for any future uses man..

[mirchi_bajji]

2 minutes ago, JambaKrantu said:

They will just stockpile it for any future uses man..

not much use man....there are better malaria drugs now

[JambaKrantu]

4 minutes ago, mirchi_bajji said:

not much use man....there are better malaria drugs now

They will dump it in the ocean man who cares, medicine cost jujupi thatha ki..

[tom bhayya]

17 minutes ago, JambaKrantu said:

Mandu dorikite vaccine enduku..

prevention is important

[veeraveeraleaks]

Much need bump in stockmarket. Ninna Johnson and johnson work avvakapothe ivvala Gilead tho news aaaa. 

Awesome. Nammakam ledhu dhora

[DummyVariable]

Remedesivir already known medicine

[JambaKrantu]

Slawomir Michalak, a 57-year-old factory worker from a suburb west of Chicago, was among the participants in the Chicago study. One of his daughters started feeling ill in late March and was later diagnosed with mild Covid-19. Michalak, by contrast, came down with a high fever and reported shortness of breath and severe pain in his back.

“It felt like someone was punching me in the lungs,” he told STAT.

At his wife’s urging, Michalak went to the University of Chicago Medicine hospital on Friday, April 3. His fever had spiked to 104 and he was struggling to breath. At the hospital, he was given supplemental oxygen. He also agreed to participate in Gilead’s severe Covid-19 clinical trial. 

His first infusion of remdesivir was on Saturday, April 4. “My fever dropped almost immediately and I started to feel better,” he said. 

By his second dose on Sunday, Michalak said he was being weaned off oxygen. He received two more daily infusions of remdesivir and recovered enough to be discharged from the hospital on Tuesday, April 7. 

“Remdesivir was a miracle,” he said. 

[mustang302]

1 minute ago, JambaKrantu said:

Slawomir Michalak, a 57-year-old factory worker from a suburb west of Chicago, was among the participants in the Chicago study. One of his daughters started feeling ill in late March and was later diagnosed with mild Covid-19. Michalak, by contrast, came down with a high fever and reported shortness of breath and severe pain in his back.

“It felt like someone was punching me in the lungs,” he told STAT.

At his wife’s urging, Michalak went to the University of Chicago Medicine hospital on Friday, April 3. His fever had spiked to 104 and he was struggling to breath. At the hospital, he was given supplemental oxygen. He also agreed to participate in Gilead’s severe Covid-19 clinical trial. 

His first infusion of remdesivir was on Saturday, April 4. “My fever dropped almost immediately and I started to feel better,” he said. 

By his second dose on Sunday, Michalak said he was being weaned off oxygen. He received two more daily infusions of remdesivir and recovered enough to be discharged from the hospital on Tuesday, April 7. 

“Remdesivir was a miracle,” he said. 

Daaaaamn daniel..good news..!

[Sucker]

basically @perugu_vada veyyali kada ilanti news 

[Android_Halwa]

This is good news..!!

Trails successful aithe, manufacturing and supplying ki ledu ledu anna kuda oka 1-2 months padutundi kada, logistical reason , regulatory approvals etc..

Atleast we have a treatment..

[argadorn]

Mana India lo Deni stock ledhu anta ... As this is used for ebola ...India lo ledhu kabati ... So Mana Indian pharmacy vallu last week start chesaru so it might take Atleast 1month to get ready India lo ...

[argadorn]

E sandarbhamu lo oka peg thagutha e roju

[tacobell fan]

Ready to re-open the Country antunna @Sucker

[tacobell fan]

20 minutes ago, Sucker said:

basically @perugu_vada veyyali kada ilanti news 

chala expect chestunnav ga

[sri_india]

14 minutes ago, argadorn said:

E sandarbhamu lo oka peg thagutha e roju

Also see the side effects before going to have your peg .....

1 in 4 patients experienced severe side effects, including multiple-organ dysfunction syndrome, septic shock, acute kidney injury and low blood pressure. 23% showed signs of liver damage on lab tests. 4 patients had to stop receiving infusions of the drug entirely